Ovarian Cancer Drug Rubraca (rucaparib) Given Fast-Track Approval

MONDAY, Dec. 19, 2016 — The anti-cancer drug Rubraca (rucaparib) has been granted accelerated approval by the U.S. Food and Drug Administration to treat advanced ovarian cancer.
The approval is limited to cases where the cancer is caused by…
Source: Topamax